NUVL logo

Nuvalent, Inc. Class A Common Stock


NUVL: Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.


Show NUVL Financials

Consumer Interest
SEC Filings

Recent trades of NUVL by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by NUVL's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Heteroaromatic macrocyclic ether chemotherapeutic agents Jun. 06, 2023
  • Patent Title: Heteroaromatic macrocyclic ether chemotherapeutic agents Jan. 03, 2023
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of NUVL in WallStreetBets Daily Discussion


Recent insights relating to NUVL

CNBC Recommendations

Recent picks made for NUVL stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in NUVL

Corporate Flights

Flights by private jets registered to NUVL